Mol.Wt. R % yield M.P. 5a 304 H 51.08% 165-167ºC 5b 338.5 Cl 47.36% 160-162ºC 5c 318 CH3 35.9% 155-157ºC 5d 334 -OCH3 49.10% 158-160ºC 5e 347 37.70% 175ºC Step-5 Synthesis of title compounds54 (7) Equimolar amounts (0.05M) of 2-Methyl-3-[5-(4-substituted) phenyl-1,3,4-oxadiazole-2-yl]-quinazoline-4(3H)-one and the opportune benzaldehyde were reacted in glacial acetic (5.2ml) under reflux for 18 hrs. A sticky oily matter was obtained, which was then purified to remove impurities to get final product. Final compound was dried and recrystallised from hot ethanol.
(5-Amino-tetrazol-1-yl)-acetic acid: Yield: 45.41%; white crystals; m.p 210-213°C; IR (KBr): 3388, 3315, 3270, 3205, 3010, 2976, 1697, 1638, 1586, 1496, 1257 cm-1; 13C NMR (75 MHz (DMSO-d6)): 168, 156, 46. (5-nitroiminotetrazole-1-yl)-acetic acid. NH4NO3 (0.60 g, 9. 09 mmol) was dissolved in H2SO4 (98%, 6 mL). The reaction mixture was cooled to 0-4 °C.
The supernatant was assayed for SOD activity by following the inhibition of epinephrine auto-oxidation. 0.5ml of sample was diluted with 0.5 ml of distilled water, to this 0.25 ml ethanol, 0.5 ml of chloroform (all reagents chilled) was added. The mixture was shaken for 1 min and centrifuged at 2000 rpm for 20 min. The enzymatic activity in supernatant was determined. To 0.05 ml of carbonate buffer (0.05 M, pH 10.2) and 0.5 ml of EDTA (0.49 M) was added.
Briefly, a solution containing 0.3 gr (3 mmol) succinic anhydride and 0.4 ml (3 mmol) of triethylamine in 10 ml of THF was dropwise added to a stirred solution of 1 mmol of sPEG in 10 ml of anhydrous THF for 12 h at 75 C. The solvent of product solution was evaporated by a rotary evaporator and the obtained dark yellow viscous liquid was dissolved in acidic water (pH= 3). In the following,
Then it is sonicated it for 10mint. TRAIL METHOD-III Mobile phase Mixed Phosphate Buffer (55:45) λmax 270 nm Flow Rate 1ml/min Column Inertsil C8 150 x 4.6 mm Retention Time 1.567 min Efficiency 999 Preparation of mobile phase Take 16.25gm of potassium dihydrogen phosphate and 0.3gm of dipotassium phosphate in volumetric flask and make volume up to 550ml by adding phosphate buffer to it , 450ml of Acetonitrile is added to the above one and made volume to 1000ml. Then it is sonicated for 10mint. TRAIL METHOD-IV Mobile phase Mixed Phosphate Buffer (55:45) λmax 270 nm Flow Rate 1ml/min Column Inertsil C18 250 x 4.6 mm Retention Time 2.713 min Efficiency
Figure 1 shows the diluted and actual concentrations of salicylic acid, the concentration and log value of aspirin at various times. Time / min C1 / mol L-1 C2 (actual) / mol L-1 [Aspirin] / mol L-1 ln([Aspirin]) 0 1.996*10-5 9.98*10-4 0.0225 -3.79 10th 6.925*10-5 3.46*10-3 0.0200 -3.91 20th 1.135*10-4 5.68*10-3 0.0178 -4.03 30th 1.372*10-4 6.86*10-3 0.0166 -4.10 40th 1.653*10-4 8.27*10-3 0.0152 -4.18 50th 1.828*10-4 9.14*10-3 0.0144 -4.24 60th 1.953*10-4 9.77*10-3 0.0137 -4.29 Figure 1. A graph of ln([aspirin]t) against time (min) was plotted. The gradient gave the value of K, the rate constant for the reaction. Figure 2 shows the plotted graph Figure 2.
Table 2: Effect of Pronase Treatment of the Phosphoprotein Derived from the Synaptosome-Enriched Fractiona5. Treatment Total dpm in the Total dpm in the supernatant ( S ) phosphoprotein residue [S/(S + R)] 100 after digestion of after digestion the phosphoprotein ( R ) 33P 32P 33P 32P 33P 32P Pronase 180 684 30 173 86 78 Control 8 72 773 3 8 Alkaline Phosphatase 1571 886 176 109 90 89 Control 224 122 1445 1053 13 10
Oxis Turbohaler 1.0 Generic Drug Name; Preparation/Formulation Oxis (Formoterol); Oxis Turbuhaler; Oxis (Eformoterol fumarate dihydrate for inhalation) 1.1 Oxis Turbohaler 6, inhalation powder • Each delivered dose of Oxis Turbohaler 6 (i.e. the dose leaving the mouthpiece) contains 4.5 micrograms formoterol fumarate dihydrate which is derived from a metered dose of 6 micrograms. • Diluents: Lactose Monohydrate 895 micrograms per delivered dose, corresponding to 1005 micrograms per metered dose. 1.2 Oxis Turbohaler 12, inhalation powder • Each delivered dose of Oxis Turbohaler 12 (i.e. the dose leaving the mouthpiece) contains 9 micrograms formoterol fumarate dihydrate which is derived from a metered dose of 12 micrograms.
Preparation of the Schiff base metal (II) complexes : An ethanolic (20 ml) solution of schiff base ligand (40mmol, 0.11g ) was added drop wise to 20ml of the metal(II) salts [20mmol, 0.04g of CuCl2.4H2O, 0.048g of CoCl2.6H2O, 0.048g of CrCl3.6H2O, and 0.044g of ZnCl2.2H2O] in boiling ethanol(78.70C). The reactions took place in 2:1 mole ratio of HL: metal (II). The reaction mixture was refluxed for 4-6hrs on a water bath and the volume of the solution was reduced to half of the initial volume. The product obtained was filtered, washed with water, diethyl ether and then dried in a vacuum over CaCl2 [16, 17]. 3.
Strength to Weight Ratio 9 kN-m/kg vii. Tensile Strength: Ultimate (UTS) 10 Pa (1.5 x 103 psi) 5.1.2 Solubility PCL is soluble in chloroform, dichloromethane, carbon tetrachloride, benzene, toluene, cyclohexanone and 2-nitropropane at room temperature. It has a low solubility in acetone, 2-butanone, ethyl acetate, dimethylformamide and acetonitrile and is insoluble in alcohol, petroleum ether and diethyl ether. 5.1.3 Biodegradable